LRRK2 (Leucine-Rich Repeat Kinase 2) Parkinson's Disease Fingerprint

计划入组 20 人 · 首次发布于 2026 年 7 月 2 日

PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)

计划入组 81 人 · 首次发布于 2012 年 2 月 22 日

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

计划入组 22 人 · 首次发布于 2022 年 4 月 27 日

Leucine rich repeat kinase 2 inhibitors (Parkinson's disease)

SY-006

WI-211094

Oxygen Rich, LLC

United States

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

Halia Therapeutics Presents LRRK2 Inhibitor HT-4253 for Neurodegenerative Diseases at BIO Investor Forum

Denali Therapeutics Initiates Phase 2a Trial of BIIB122 for LRRK2-Associated Parkinson's Disease

Parkinson's Drug DNL-151 Phase III Trial Terminated; Lerodalcibep Shows Promise in Hypercholesterolemia